American Journal of Cardiovascular Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
AbstractThe prevalence of arterial hypertension is high in patients with diabetes mellitus (DM). When DM and hypertension coexist, they constitute a dual cardiovascular threat and should be adequately controlled. Novel antihyperglycemic agents, including sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, have recently been used in the treatment of DM. Beyond their glucose-lowering effects, these drugs have shown beneficial pleiotropic cardiovascular effects, including lowering of arterial blood pressure (BP), as acknowle...
Source: American Journal of Cardiovascular Drugs - August 10, 2020 Category: Cardiology Source Type: research

Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI
AbstractThe optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention remains a controversial topic. The European Society of Cardiology and the American College of Cardiology/American Heart Association recommend at least 6 and 12  months of DAPT after PCI in patients with stable coronary artery disease or acute coronary syndrome, respectively. Although prolonging DAPT duration reduces ischemic events, it is associated with higher rates of bleeding and possible fatal outcomes. The DAPT score can be an important tool to ident ify patients who may still benefit from prolonged therapy. Neve...
Source: American Journal of Cardiovascular Drugs - August 10, 2020 Category: Cardiology Source Type: research

Author ’s Reply to Vaz et al.: “Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - August 10, 2020 Category: Cardiology Source Type: research

Comment on: Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - August 10, 2020 Category: Cardiology Source Type: research

Current Overview on Hypercoagulability in COVID-19
AbstractThe coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensiv...
Source: American Journal of Cardiovascular Drugs - August 3, 2020 Category: Cardiology Source Type: research

Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 31, 2020 Category: Cardiology Source Type: research

Author ’s Reply to Peverill: “Predictors of Left Ventricular Dysfunction in Friedreich’s Ataxia in a 16-Year Observational Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 24, 2020 Category: Cardiology Source Type: research

Comment on: “Predictors of Left Ventricular Dysfunction in Friedreich Ataxia in a 16-Year Observational Study”
(Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 24, 2020 Category: Cardiology Source Type: research

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure
ConclusionThis independent ex ante economic evaluation suggests that genetically targeted treatment with bucindolol is unlikely to yield clinicoeconomic benefits over empirical treatment with carvedilol in NYHA III/IV HF. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 24, 2020 Category: Cardiology Source Type: research

Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis
ConclusionsNebivolol demonstrated at least similar control of blood pressure levels in hypertensive individuals when compared with drugs of the most used classes. In addition, in relation to the control of arterial hypertension, studies with clinical outcomes should be performed to ensure the use of this drug in detriment to others with these well-established results. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 24, 2020 Category: Cardiology Source Type: research

Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia
AbstractRosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particularly strong inhibitory effects on hepatic cholesterol synthesis, and ezetimibe, which inhibits the intestinal absorption of cholesterol. A fixed-dose combination (FDC) of rosuvastatin/ezetimibe is indicated as an adjunctive therapy to diet for the management of primary hypercholesterolemia in adults in numerous countries worldwide. In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvasta...
Source: American Journal of Cardiovascular Drugs - July 9, 2020 Category: Cardiology Source Type: research

COVID-19 Pandemic: Cardiovascular Complications and Future Implications
AbstractCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a global pandemic with the highest number of affected individuals in the modern era. Not only is the infection inflicting significant morbidity and mortality, but there has also been  a significant strain to the health care system and the economy. COVID-19 typically presents as viral pneumonia, occasionally leading to acute respiratory distress syndrome (ARDS) and death. However, emerging evidence suggests that it has a significant impact on the cardiovascular (CV) system by di rect myocardial damage...
Source: American Journal of Cardiovascular Drugs - June 22, 2020 Category: Cardiology Source Type: research

Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome
ConclusionsEnoxaparin was associated with a lower risk of ischemic complications (including death), lower costs, and better safety than UFH among NSTEMI patients. Improving upstream selection of anticoagulants in appropriate populations may help optimize clinical outcomes and costs. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - June 22, 2020 Category: Cardiology Source Type: research

The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis
ConclusionOur study suggests a favorable risk –benefit profile of rivaroxaban, with superior efficacy and safety over warfarin in patients with AF and diabetes. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - June 7, 2020 Category: Cardiology Source Type: research

PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks
ConclusionsConsistent with clinical trial findings, alirocumab and evolocumab improved lipid levels in a real-world setting in patients with high baseline LDL-C levels despite receiving maximally tolerated LLTs. PCSK9i were generally well-tolerated. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - June 7, 2020 Category: Cardiology Source Type: research